Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ETCompany ParticipantsBrian Luque – Head of Investor Relations ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...

More participants in the higher-dose group than placebo achieved an HbA1c under 7% (55.9% vs 15.2%) or under 6.5% (29.4% vs 6 ...

From new immunotherapy data to managing pollution's impact on kids' allergies, recent months have held significant ...

Studies show that oatmeal has many health benefits, from weight loss and lowering blood sugar levels to reduced risk of heart ...

A new clinical trial finds no cardiovascular benefit from high-dose multivitamins, with or without chelation therapy, in ...

Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY ...

A clinical trial to test the effectiveness of a new, plant-based oral drug to treat type 2 diabetes has produced some ...

Kucirkova: Instead of debating randomized controlled trials versus co-design, it’s time to completely rethink the way these tools are assessed.

Data show minimal risk of stopping DMTs in older MS patients with stable disease. Now, the focus has shifted to understanding ...

ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter ...

Axsome Therapeutics (AXSM) has received formal pre-New Drug Application meeting minutes from the U.S. Food and Drug Administration supporting a ...